Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1757636 | 0.89 | PTGDR2 (0.75) | PTGDR2 | |
| SCHEMBL1757334 | 0.88 | PTGDR2 (0.77) | PTGDR2 | |
| SCHEMBL1757679 | 0.86 | PTGDR2 (0.80) | PTGDR2ALDH1A1MAPK1STAT3RAB9A | |
| SCHEMBL1757674 | 0.85 | PTGDR2 (0.69) | PTGDR2ALDH1A1MAPK1STAT3KDM4E | |
| SCHEMBL1757270 | 0.85 | PTGDR2 (0.81) | PTGDR2RAB9A | |
| SCHEMBL1757689 | 0.84 | PTGDR2 (1.00) | PTGDR2ALDH1A1RAB9A | |
| SCHEMBL1757543 | 0.83 | PTGDR2 (0.66) | PTGDR2ALDH1A1MAPK1STAT3KDM4E | |
| SCHEMBL1757471 | 0.82 | PTGDR2 (0.74) | PTGDR2ALDH1A1MAPK1STAT3RAB9A | |
| SCHEMBL1757515 | 0.82 | PTGDR2 (0.77) | PTGDR2ALDH1A1HPGDRAB9A | |
| SCHEMBL1757388 | 0.82 | PTGDR2 (0.64) | PTGDR2ALDH1A1MAPK1STAT3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011055270-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH LLC (US) | 2011-05-12 | — | — | WO | claimed |
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH, LLC (US) | 2011-05-05 | — | — | US | claimed |
| WO-2011055270-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH, LLC (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | HRH2, CRHR2, CRHR1 | PTGDR2 13/4885ALDH1A1 1069/4885MAPK1 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.